埃克斯坦巴尔病毒相关胃癌的展望。
Outlooks on Epstein-Barr virus associated gastric cancer.
机构信息
Division of Medical Oncology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, USA.
Division of Hematology/Oncology, Department of Medicine, St. Michael's Hospital, University of Toronto, Canada.
出版信息
Cancer Treat Rev. 2018 May;66:15-22. doi: 10.1016/j.ctrv.2018.03.006. Epub 2018 Mar 31.
Abstract
Epstein-Barr virus associated gastric cancer (EBVaGC) comprises approximately 10% of gastric carcinomas. Multiple factors contribute to tumorigenesis, including EBV driven hypermethylation of tumor suppressor genes, inflammatory changes in gastric mucosa, host immune evasion by EBV and changes in cell cycle pathways. The unique molecular characteristics of EBVaGC, such as programmed death ligand 1 (PD-L1) overexpression, highlight the potential for using EBV as a biomarker for response to immunotherapy. Few studies have reported benefit from immunotherapy in EBV positive cancers, and clinical trials investigating the impact of checkpoint inhibitors in EBVaGC are currently underway. This review provides the most recent updates on molecular pathophysiology, epidemiology, clinical features and treatment advances pertaining to EBVaGC.
摘要
EB 病毒相关胃癌（EBVaGC）约占胃癌的 10%。多种因素导致肿瘤发生，包括 EBV 驱动的肿瘤抑制基因异常甲基化、胃黏膜炎症改变、EBV 引起的宿主免疫逃逸以及细胞周期通路改变。EBVaGC 的独特分子特征，如程序性死亡配体 1（PD-L1）过表达，提示 EBV 作为免疫治疗反应生物标志物的潜力。少数研究报告 EBV 阳性癌症从免疫治疗中获益，目前正在进行临床试验以研究检查点抑制剂对 EBVaGC 的影响。本文就 EBVaGC 的分子病理生理学、流行病学、临床特征和治疗进展的最新研究进行综述。
相似文献
1
Outlooks on Epstein-Barr virus associated gastric cancer.埃克斯坦巴尔病毒相关胃癌的展望。
Cancer Treat Rev. 2018 May;66:15-22. doi: 10.1016/j.ctrv.2018.03.006. Epub 2018 Mar 31.
2
Epstein-Barr virus-associated gastric cancer: A distinct subtype.EBV 相关胃癌：一种独特的亚型。
Cancer Lett. 2020 Dec 28;495:191-199. doi: 10.1016/j.canlet.2020.09.019. Epub 2020 Sep 23.
3
Transcriptional analysis of immune genes in Epstein-Barr virus-associated gastric cancer and association with clinical outcomes.EB 病毒相关胃癌免疫基因的转录分析及其与临床结局的关系。
Gastric Cancer. 2018 Nov;21(6):1064-1070. doi: 10.1007/s10120-018-0851-9. Epub 2018 Jun 18.
4
Update on Epstein-Barr virus and gastric cancer (review).爱泼斯坦-巴尔病毒与胃癌的最新进展（综述）
Int J Oncol. 2015 Apr;46(4):1421-34. doi: 10.3892/ijo.2015.2856. Epub 2015 Jan 28.
5
EBV-associated gastric cancer evades T-cell immunity by PD-1/PD-L1 interactions.EBV 相关胃癌通过 PD-1/PD-L1 相互作用逃避 T 细胞免疫。
Gastric Cancer. 2019 May;22(3):486-496. doi: 10.1007/s10120-018-0880-4. Epub 2018 Sep 28.
6
Epstein-Barr Virus-associated Gastric Cancer and Potential Mechanisms of Oncogenesis.EB 病毒相关性胃癌及其致癌的潜在机制。
Curr Cancer Drug Targets. 2017;17(6):534-554. doi: 10.2174/1568009616666160926124923.
7
Epstein-Barr Virus Positive Gastric Cancer: A Distinct Subtype Candidate for Immunotherapy.EBV 阳性胃癌：免疫治疗的一个独特候选亚型。
J Surg Res. 2021 May;261:130-138. doi: 10.1016/j.jss.2020.12.029. Epub 2021 Jan 8.
8
Efficacy and predictive biomarkers of immunotherapy in Epstein-Barr virus-associated gastric cancer.免疫治疗在 Epstein-Barr 病毒相关性胃癌中的疗效和预测生物标志物。
J Immunother Cancer. 2022 Mar;10(3). doi: 10.1136/jitc-2021-004080.
9
Novel Therapeutic Approaches for Epstein-Barr Virus Associated Gastric Cancer.新型治疗方法用于治疗 Epstein-Barr 病毒相关胃癌。
Anticancer Res. 2019 Aug;39(8):4003-4010. doi: 10.21873/anticanres.13555.
10
Immune Landscape of Epstein-Barr Virus-Associated Gastric Cancer: Analysis From a Western Academic Institution.EBV 相关胃癌的免疫景观：来自西方学术机构的分析。
J Surg Res. 2024 Apr;296:742-750. doi: 10.1016/j.jss.2024.01.043. Epub 2024 Feb 17.
引用本文的文献
1
Targeting archetypes of viral-driven cancers with immunotherapy: a perspective on immunogenicity within the tumor microenvironment.用免疫疗法靶向病毒驱动癌症的原型：关于肿瘤微环境中免疫原性的观点
Front Immunol. 2025 Aug 29;16:1631258. doi: 10.3389/fimmu.2025.1631258. eCollection 2025.
2
A Longitudinal Study of Premalignant Gastric Lesions and Early Onset Gastric Cancer Among Young Adults in Central Saudi Arabia.沙特阿拉伯中部年轻成年人癌前胃病变和早发性胃癌的纵向研究。
Curr Oncol. 2025 Jul 30;32(8):428. doi: 10.3390/curroncol32080428.
3
Global Epidemiology of PD-L1 Expression in Epstein-Barr Virus-Associated Gastric Cancer: A Systematic Review and Meta-Analysis.EB病毒相关胃癌中PD-L1表达的全球流行病学：一项系统评价和荟萃分析
J Gastrointest Cancer. 2025 Aug 26;56(1):178. doi: 10.1007/s12029-025-01305-w.
4
Epstein-Barr virus-coded miR-BART19-3p promotes proliferation of EBV-associated gastric cancer by inhibiting GADD45B.爱泼斯坦-巴尔病毒编码的miR-BART19-3p通过抑制GADD45B促进EB病毒相关胃癌的增殖。
J Transl Med. 2025 Aug 25;23(1):956. doi: 10.1186/s12967-025-06955-9.
5
Epstein-Barr virus modulates iron metabolism and ferritin expression to promote tumorigenesis in gastric cancer.爱泼斯坦-巴尔病毒调节铁代谢和铁蛋白表达以促进胃癌的肿瘤发生。
J Mol Histol. 2025 Jul 18;56(4):231. doi: 10.1007/s10735-025-10515-2.
6
Distribution and Clinical Impact of Virulence Factors in Epstein-Barr-Virus-Associated Gastric Cancer.爱泼斯坦-巴尔病毒相关胃癌中致病因素的分布及其临床影响
Antibiotics (Basel). 2025 Jun 5;14(6):580. doi: 10.3390/antibiotics14060580.
7
[Viral Infection in Upper Gastrointestinal Tract].[上消化道病毒感染]
Korean J Helicobacter Up Gastrointest Res. 2024 Jun;24(2):122-126. doi: 10.7704/kjhugr.2024.0027. Epub 2024 Jun 10.
8
TAP1 promotes immune escape by activating JNK/STAT1/PD-L1 signaling in EBV-associated gastric cancer.TAP1通过激活EB病毒相关胃癌中的JNK/STAT1/PD-L1信号通路促进免疫逃逸。
Mol Cell Biochem. 2025 Jun 11. doi: 10.1007/s11010-025-05319-7.
9
Selected Alu methylation levels in the gastric carcinogenesis cascade.胃癌发生级联反应中选定的Alu甲基化水平。
PeerJ. 2025 May 20;13:e19485. doi: 10.7717/peerj.19485. eCollection 2025.
10
Viral oncogenesis in cancer: from mechanisms to therapeutics.癌症中的病毒致癌作用：从机制到治疗
Signal Transduct Target Ther. 2025 May 12;10(1):151. doi: 10.1038/s41392-025-02197-9.
本文引用的文献
1
The Changing Face of Noncardia Gastric Cancer Incidence Among US Non-Hispanic Whites.美国非西班牙裔白人中非贲门胃癌发病率的变化情况。
J Natl Cancer Inst. 2018 Jun 1;110(6):608-615. doi: 10.1093/jnci/djx262.
2
Immune Activation and Benefit From Avelumab in EBV-Positive Gastric Cancer.免疫激活与avelumab 在 EBV 阳性胃癌中的获益
J Natl Cancer Inst. 2018 Mar 1;110(3):316-320. doi: 10.1093/jnci/djx213.
3
Clinicopathological factors associated with HER2-positive gastric cancer: A meta-analysis.与HER2阳性胃癌相关的临床病理因素：一项荟萃分析。
Medicine (Baltimore). 2017 Nov;96(44):e8437. doi: 10.1097/MD.0000000000008437.
4
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial.纳武利尤单抗治疗既往至少两种化疗方案治疗失败或不耐受的晚期胃或胃食管结合部腺癌患者（ONO-4538-12，ATTRACTION-2）：一项随机、双盲、安慰剂对照、III 期临床试验。
Lancet. 2017 Dec 2;390(10111):2461-2471. doi: 10.1016/S0140-6736(17)31827-5. Epub 2017 Oct 6.
5
PD-L1 and gastric cancer prognosis: A systematic review and meta-analysis.程序性死亡受体 1 配体（PD-L1）与胃癌预后：一项系统评价和荟萃分析。
PLoS One. 2017 Aug 10;12(8):e0182692. doi: 10.1371/journal.pone.0182692. eCollection 2017.
6
Clinical Significance of Four Molecular Subtypes of Gastric Cancer Identified by The Cancer Genome Atlas Project.癌症基因组图谱计划所鉴定的胃癌四种分子亚型的临床意义
Clin Cancer Res. 2017 Aug 1;23(15):4441-4449. doi: 10.1158/1078-0432.CCR-16-2211.
7
A BARF1-specific mAb as a new immunotherapeutic tool for the management of EBV-related tumors.一种针对BARF1的单克隆抗体作为治疗EBV相关肿瘤的新型免疫治疗工具。
Oncoimmunology. 2017 Mar 16;6(4):e1304338. doi: 10.1080/2162402X.2017.1304338. eCollection 2017.
8
Status of Epstein-Barr Virus Coinfection with in Gastric Cancer.胃癌中爱泼斯坦-巴尔病毒合并感染的状况
J Oncol. 2017;2017:3456264. doi: 10.1155/2017/3456264. Epub 2017 Mar 21.
9
Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial.阿维鲁单抗用于治疗转移性或局部晚期经治实体瘤（JAVELIN实体瘤研究）：一项1a期、多队列、剂量递增试验
Lancet Oncol. 2017 May;18(5):587-598. doi: 10.1016/S1470-2045(17)30239-5. Epub 2017 Mar 31.
10
PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing l-asparaginase.帕博利珠单抗的 PD1 阻断在 l-天冬酰胺酶治疗失败的复发或难治性 NK/T 细胞淋巴瘤中具有高度疗效。
Blood. 2017 Apr 27;129(17):2437-2442. doi: 10.1182/blood-2016-12-756841. Epub 2017 Feb 10.
Zotero 插件